Cargando…

COVID-19 vaccines: ethical framework concerning human challenge studies

BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Calina, Daniela, Hartung, Thomas, Docea, Anca Oana, Spandidos, Demetrios A., Egorov, Alex M., Shtilman, Michael I., Carvalho, Felix, Tsatsakis, Aristidis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449865/
https://www.ncbi.nlm.nih.gov/pubmed/32851596
http://dx.doi.org/10.1007/s40199-020-00371-8
_version_ 1783574706753896448
author Calina, Daniela
Hartung, Thomas
Docea, Anca Oana
Spandidos, Demetrios A.
Egorov, Alex M.
Shtilman, Michael I.
Carvalho, Felix
Tsatsakis, Aristidis
author_facet Calina, Daniela
Hartung, Thomas
Docea, Anca Oana
Spandidos, Demetrios A.
Egorov, Alex M.
Shtilman, Michael I.
Carvalho, Felix
Tsatsakis, Aristidis
author_sort Calina, Daniela
collection PubMed
description BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses. OBJECTIVES: To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, RESULTS: Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika. CONCLUSIONS: One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7449865
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74498652020-08-27 COVID-19 vaccines: ethical framework concerning human challenge studies Calina, Daniela Hartung, Thomas Docea, Anca Oana Spandidos, Demetrios A. Egorov, Alex M. Shtilman, Michael I. Carvalho, Felix Tsatsakis, Aristidis Daru Short Communication BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses. OBJECTIVES: To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, RESULTS: Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika. CONCLUSIONS: One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives. GRAPHICAL ABSTRACT: [Image: see text] Springer International Publishing 2020-08-27 /pmc/articles/PMC7449865/ /pubmed/32851596 http://dx.doi.org/10.1007/s40199-020-00371-8 Text en © Springer Nature Switzerland AG 2020
spellingShingle Short Communication
Calina, Daniela
Hartung, Thomas
Docea, Anca Oana
Spandidos, Demetrios A.
Egorov, Alex M.
Shtilman, Michael I.
Carvalho, Felix
Tsatsakis, Aristidis
COVID-19 vaccines: ethical framework concerning human challenge studies
title COVID-19 vaccines: ethical framework concerning human challenge studies
title_full COVID-19 vaccines: ethical framework concerning human challenge studies
title_fullStr COVID-19 vaccines: ethical framework concerning human challenge studies
title_full_unstemmed COVID-19 vaccines: ethical framework concerning human challenge studies
title_short COVID-19 vaccines: ethical framework concerning human challenge studies
title_sort covid-19 vaccines: ethical framework concerning human challenge studies
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449865/
https://www.ncbi.nlm.nih.gov/pubmed/32851596
http://dx.doi.org/10.1007/s40199-020-00371-8
work_keys_str_mv AT calinadaniela covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT hartungthomas covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT doceaancaoana covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT spandidosdemetriosa covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT egorovalexm covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT shtilmanmichaeli covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT carvalhofelix covid19vaccinesethicalframeworkconcerninghumanchallengestudies
AT tsatsakisaristidis covid19vaccinesethicalframeworkconcerninghumanchallengestudies